exploratory trial of a WT1-W10 immunotherapy against pancreatic cancer in combination with the standard S1 chemotherapy.
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000026049
- Lead Sponsor
- Anti-tumor Immunotherapy Research Network, Department of Immunology, Shool Of Medicine, Kochi Univesity
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Not provided
1) Patients with uncontrollable infectious diseases (including active Tuberculosis) 2) patients with severe complications (malignant lypertension, severe congestive heart failure, severe colonary in sufficiency, myocardial, infarction within three months, terminal, stage of liver cirrhousis, uncontrollable diabetes mellitus, severe pulmonary fibrosis, active interstitial pneumonitis, etc.) 3) patients with serious comorbidities (generally those of NCI-CTC ver 3.0 grade 3 or higher) 4) patients who have been under parenteral nutrition for more than 24 hours due to impairment of digestive organs. 5) liver metastasis occupying more than 1/3 of the liver 6) Patients with active concomitant malignancy 7) patients with hematopoietic malignancies including MDS, MDS/MPD, CML 8) patients who have received bone marrow or hematopoietic stem cell transplantation 9) pregnant women, breast feeding mothers 10) patients with serious psychological disorders 11) patients whose participation to the study is considered inappropriate by the doctors for various reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The type and frequency of adverse events by the CTCAE criteria
- Secondary Outcome Measures
Name Time Method W10-specific T cell responses, DTH (delayed type hypersensitivity)